1 October 2024

Highlights in Medicinal Chemistry V

Organised by:

SCI’s Fine Chemicals Group

SCI, London, UK

Register Now

Prices start from £95.00

Early bird offer ends 3 September 2024


This meeting aims to showcase vignettes of modern medicinal chemistry to bring new thinking to the subject, challenge perceptions and encourage scientific interaction between researchers. The short presentation format of the meeting also aims to provide a focussed forum to promote examples of medicinal chemistry excellence.


This meeting is targeted at academic and industrial scientists engaged in all aspects of the drug discovery process and those interested in broadening their knowledge at the forefront of medicinal chemistry.

Plenary Speakers

Prof Ed Tate

Imperial College London

Ed holds the GSK Chair in Chemical Biology at Imperial College London, he is also Group Leader at the Francis Crick Institute, and academic founder of Myricx Bio, a biotech company developing his lab’s research toward clinical applications. Following his PhD (2000) with Steve Ley in Cambridge and postdoctoral research in Paris, he was awarded a BBSRC David Phillips Fellowship in 2006 to start his group at Imperial College. He sits on the advisory boards of several international research institutes and biotechs, and develops new drug discovery technologies with companies including Pfizer, GSK and AstraZeneca. His research has been recognised by multiple awards and Fellowships including the 2020 Corday-Morgan Prize of the Royal Society of Chemistry and a 2022 Cancer Research UK Programme Award. In 2023 he was appointed to the GSK Endowed Chair in Chemical Biology at Imperial College.

Dr Suzanne O Connor

Centre for Targeted Protein Degradation Dundee

Suzanne is a Senior Drug Discovery Scientist at the University of Dundee where she leads PROTAC drug discovery projects for the treatment of cancer, in collaboration with Alessio Ciulli and Boehringer Ingelheim. She has a Medicinal Chemistry degree from Trinity College Dublin, a Research Masters in Drug Discovery and Development from Imperial College London and a PhD in Fragment Based Drug Discovery from the Institute of Cancer Research, under the supervision of Prof. Ian Collins. Prior to joining the Centre for Targeted Protein Degradation in Dundee, Suzanne has worked at Evotec in lead optimisation drug discovery for the treatment of chronic pain, and at AstraZeneca working on a variety of oncology drug discovery projects.

Dr Ingo Hartung

Merck Healthcare

Ingo Hartung is a synthetic organic chemist by training (PhD University of Hannover/Germany, Postdoc Stanford University/US) with more than 15 years of Pharma industry experience (Schering AG, Bayer AG, Merck KGaA). He has been project leader in oncology and cardiology NCE drug discovery and has had portfolio responsibility for preclinical research in the areas of epigenetics and immuno-oncology. In his current role he is head of Merck’s Medicinal Chemistry & Drug Design department and is leading Merck’s global cross-functional targeted protein degradation platform. His research interests comprise all aspects of innovation in small molecule drug discovery with a special focus on new synthetic modalities like protein degraders. He is the author of >50 scientific publications and patents.


Tuesday 1 October 2024

Registration and refreshments
Opening remarks
Modulating protein-protein interactions in immunology: from chemical biology to covalent ligand discovery
Ed Tate, Imperial College London
Developing PROTACs targeting the MAPK Pathway
Suzanne O'Connor, Centre for Targeted Protein Degradation Dundee
Refreshment break
A Multistep High-Throughput Chemistry Direct-to-Biology Platform to take PROTAC Synthesis and Testing to a New Level
Rebecca Stevens, GSK / University of Strathclyde
Deep learning guided identification of peripherally restricted MAGL inhibitors
Fionn O’Hara, F. Hoffmann-La Roche Ltd
Accelerating BRPF1b hit identification with BioPhysical and Active Learning Screening (BioPALS)
Tom Pesnot, Concept Life Sciences
Synthesis of Aryl-fused Bicyclo[3.1.1]heptanes (BCHeps) and Validation as Naphthyl Bioisosteres
Pol Hernández-Lladó, University of Oxford
Novel Macrocyclic NLRP3 inhibitors
Jonathan Shannon, Sygnature Discovery
Discovery of Hedgehog Acyltransferase (HHAT) Inhibitors as a Novel Strategy to Stop Hedgehog Signalling in Cancer
Efthymios S. Gavriil, Imperial College London
Refreshment break
Discovery of a novel selective warhead to covalently target Asp12 in K-Ras G12D
Ludovica Sirocchi, Boehringer Ingelheim
Development of a Series of Pyrrolopyridone MAT2a Inhibitors
Stephen Atkinson, AstraZeneca
Quo vadis? Small molecule drug discovery
Ingo Hartung, Merck Healthcare
Closing remarks
Networking reception


SCI’s Fine Chemicals Group are committed to promoting diversity and equality in the chemical sciences. We aim to identify high quality speakers for all our conferences with full inclusivity where attendees from all backgrounds are welcome. We are open to offering flexible presentation options.


Accessibility Grants

SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.

Sponsorship and exhibition information

For further information and prices, please email conferences@soci.org.

Venue and Contact


14/15 Belgrave Square

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org

Early bird - ends Tuesday 3 September 2024
SCI Member - £95
Non-member - £125
Student Member - £50

After early bird
SCI Member - £145
Non-member - £175
Student Member - £80

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations

Booking Process/Deadlines

Booking terms and conditions

CPD Info

SCI Members attending this meeting are able to claim CPD points.

Accredited cpd Centre - The CPD Standards Office - CPD Provider 41057 - www.cpdstandards.com



Organising committee
Dr Nicola Chessum, SCI / Boehringer Ingelheim RCV GmbH & Co KG
Dr Helen Horsley, SCI / UCB
Dr Sarah Major,  SCI / Dark Blue Therapeutics
Dr Joanne Pinder, SCI / Vertex Pharmaceuticals (Europe) Ltd
Dr Hugh Tawell, SCI / Domainex